Bristol-Myers Squibb

Bristol-Myers Squibb and Gritstone Oncology Announce Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Thu, 07/19/18 - 09:46 am
Bristol-Myers Squibb
Gritstone Oncology
Opdivo
Opdivo Gains New Approval in Combination with Yervoy
CP Wire
Wed, 07/11/18 - 11:32 am
Opdivo
Yervoy
Bristol-Myers Squibb
metastatic colorectal cancer
Opdivo Gains New Approval in Combination with Yervoy
Wed, 07/11/18 - 10:11 am
Bristol-Myers Squibb
Opdivdo
metastatic colorectal cancer
Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain
Endpoints
Fri, 06/22/18 - 09:57 am
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Fierce Pharma
Mon, 06/18/18 - 09:47 pm
Bristol-Myers Squibb
AbbVie
Empliciti
Multiple Myeloma
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
Motley Fool
Fri, 06/15/18 - 07:04 pm
NASH
liver disease
Viking Therapeutics
Madrigal Pharmaceuticals
Pfizer
Bristol-Myers Squibb
Gilead Sciences
Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
Endpoints
Fri, 06/15/18 - 09:37 am
Bristol-Myers Squibb
Opdivo
China
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Fri, 06/8/18 - 09:48 am
Humira
AbbVie
Keytruda
Merck
Revlimid
Celgene
Opdivo
Bristol-Myers Squibb
ASCO18: 3 unanswered questions from oncology's largest conference
Biopharma Dive
Thu, 06/7/18 - 09:35 am
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
immunotherapy combinations
non-small cell lung cancer
ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
Fierce Pharma
Mon, 06/4/18 - 10:24 pm
Bristol-Myers Squibb
biomarkers
ASCO 2018
Opdivo
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Forbes
Sun, 06/3/18 - 10:00 am
Nektar
Bristol-Myers Squibb
NKTR-214
ASCO 2018
melanoma
renal cell carcinoma
urothelial cancer
Ahead of ASCO, BMS' Opdivo leads Merck's Keytruda in U.S. sales—but not for long, analyst predicts
Fierce Pharma
Fri, 06/1/18 - 11:49 am
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
5 Best-Selling Orphan Drugs in the U.S.
Motley Fool
Wed, 05/30/18 - 09:13 pm
orphan drugs
Celgene
Revlimid
Roche
Rituxan
Teva Pharmaceutical
Copaxone
Opdivo
Bristol-Myers Squibb
Merck
Keytruda
Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Endpoints
Tue, 05/29/18 - 08:54 am
Roche
Tecentriq
anti-PD-L1
non-squamous non-small cell lung cancer
Merck
Bristol-Myers Squibb
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
Mon, 05/28/18 - 02:14 pm
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
BMY Is Rapidly Advancing Its First-Line NSCLC Research Program
Market Realist
Mon, 05/28/18 - 01:26 pm
Bristol-Myers Squibb
Opdivo
non-small cell lung cancer
Yervoy
Cancer drug spending climbs, with top winners earning lion's share
Biopharma Dive
Fri, 05/25/18 - 10:04 am
drug spending
oncology
Merck
Bristol-Myers Squibb
5 takeaways from the first look at cancer's biggest conference
Biopharma Dive
Thu, 05/17/18 - 10:44 pm
ASCO
Regeneron
cemiplimab
Keytruda
Opdivo
Merck
Bristol-Myers Squibb
Nektar
NKTR-214
Loxo Oncology
LOXO-292
Jounce Therapeutics
JTX-2011
Who do you trust? For doctors, it's Bristol Myers-Squibb and Biogen
Fierce Pharma
Wed, 05/9/18 - 09:25 am
physicians
digital marketing
Bristol-Myers Squibb
Biogen
Celgene
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer
CP Wire
Thu, 05/3/18 - 11:16 am
Bristol-Myers Squibb
Opdivo
Yervoy
metastatic non-small cell lung cancer
EMA
Europe

Pages